Author:
Rojas J M,Knight K,Wang L,Clark R E
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference26 articles.
1. Clark RE, Christmas SE . BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia. Leuk Lymphoma 2001; 42: 871–880.
2. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85: 2680–2684.
3. Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, MacIntyre AR et al. Direct evidence that leukaemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887–2893.
4. Posthuma EF, van Bergen CA, Kester MG, de Paus RA, van Veelen PA, de Ru AH et al. Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated. Haematologica 2004; 89: 1062–1071.
5. Butt NM, Rojas JM, Wang L, Christmas SE, Abu-Eisha HM, Clark RE . Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. Haematologica 2005; 90: 1315–1323.
Cited by
100 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献